Premium
Efficacy of low‐dose dexamethasone in castration‐refractory prostate cancer
Author(s) -
Venkitaraman Ramachandran,
Thomas Karen,
Huddart Robert A.,
Horwich Alan,
Dearnaley David P.,
Parker Chris C.
Publication year - 2008
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2007.07261.x
Subject(s) - medicine , dexamethasone , prostate cancer , corticosteroid , prostate specific antigen , refractory (planetary science) , cohort , urology , oncology , clinical endpoint , cancer , clinical trial , physics , astrobiology
OBJECTIVE To evaluate the prostate‐specific antigen (PSA) response rate and duration of PSA response to dexamethasone in patients with castration‐refractory prostate cancer (CRPC), as corticosteroids are frequently used as second‐line hormonal treatment of CRPC and there is little published evidence concerning the efficacy of low‐dose dexamethasone in this setting. PATIENTS AND METHODS In all, 102 patients with progressive CRPC received oral dexamethasone (0.5 mg daily) between January 2003 and October 2006. The median pretreatment PSA level was 83 ng/mL. The main endpoint was the PSA response rate according to the PSA Working Group criteria. RESULTS In all, 50 patients (49%) had a confirmed PSA response. The median (range) time to PSA progression for the entire cohort was 7.4 (1–28) months. In responders, the median duration of the PSA response was 11.6 (1–24) months. CONCLUSION Low‐dose dexamethasone has significant activity in CRPC. Subject to validation with more clinically meaningful endpoints, dexamethasone could become the corticosteroid of choice in the management of CRPC, and its potential for use in combination with novel agents should be explored.